A Phase II Trial of Pazopanib in Von Hippel-Lindau Syndrome.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 22 Sep 2017
At a glance
- Drugs Pazopanib (Primary)
- Indications Von Hippel-Lindau disease
- Focus Therapeutic Use
- 14 Sep 2017 Planned End Date changed from 1 Jan 2018 to 1 Jan 2019.
- 14 Sep 2017 Planned primary completion date changed from 1 Jan 2018 to 1 Jan 2019.
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology